share_log
Hi,
moomoo ID:0
Log Out
English
Back
  • English
  • 中文繁体
  • 中文简体

Global Newborn Screening Market Report to 2031 - Players Include Agilent Technologies, Bio-Rad Laboratories, Covidien and GE Healthcare - ResearchAndMarkets.com

Businesswire ·  09/30 21:06

DUBLIN--(BUSINESS WIRE)--The "Newborn Screening Market By Product Type, By Test Type, By Technology, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.


The global newborn screening market valued at $ 1,055.24 million in 2021, and is projected to reach $ 2,038.47 million by 2031, registering a CAGR of 6.8% from 2022 to 2031.

Newborn screening test is the series of test performed during the first few days of your baby's life, usually by a hospital health care practitioner. A few drops of blood from a heel prick are placed on a special card, called a Guthrie card. this card, along with your baby's details, is mailed to a specialized state laboratory, which will test the blood sample for a variety of health disorders, including CF (cystic fibrosis).

Newborn screening in certain states requires two blood samples, one at birth and the other a few weeks later. Newborn screening is essential for detection and early diagnosis of certain genetic, endocrine, and metabolic disorders, and are also tested for hearing loss and critical congenital heart defects (CCHDs).

The major factors that drive the growth of the global newborn screening market include increasing government support for newborn screening and development in screening technology. In addition, high birth rate and increasing incidence of neonatal disease propel the market growth.

However, lack of improvement in healthcare infrastructure. Conversely, screening of genetic disorders and emerging market such as Brazil, China and India provide significant opportunities to key players in this market due to increase in birth rates and rise in disposable income.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the newborn screening market analysis from 2021 to 2031 to identify the prevailing Newborn Screening Market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the newborn screening market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global newborn screening market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product Type

  • Instrument
  • Consumables

By Test Type

  • Blood test
  • Hearing screening test
  • Heart screening

By Technology

  • Tandem Mass Spectrometry (TMS)
  • Molecular Assays
  • Immunoassays and Enzymatic Assays
  • Hearing Screen Technology
  • Pulse Oximetry Screening Technology
  • Others

By End User

  • Hospitals
  • Clinical laboratories

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • Italy
  • Spain
  • Rest of Europe
  • France
  • U.K.
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Ab Sciex LLC
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Covidien Plc
  • Ge Healthcare
  • PERKINELMER, INC.
  • MASIMO CORPORATION
  • Natus Medical Incorporated
  • Trivitron Healthcare
  • Waters Corporation

For more information about this report visit


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.